Get access

Early therapy-related myeloid sarcoma and deletion of 9q22.32 to q31.1

Authors

  • Molly M. Brickler RN, MSN, CPNP-AC,

    1. Pediatric Hematology, Oncology, and Bone Marrow Transplant, Medical College of Wisconsin, Milwaukee, Wisconsin
    2. Midwest Center for Cancer and Blood Disorders, Milwaukee, Wisconsin
    Search for more papers by this author
  • Donald G. Basel MD,

    1. Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin
    Search for more papers by this author
  • Gabriela Gheorghe MD,

    1. Pediatric Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin
    Search for more papers by this author
  • David M. Margolis MD,

    1. Pediatric Hematology, Oncology, and Bone Marrow Transplant, Medical College of Wisconsin, Milwaukee, Wisconsin
    2. Midwest Center for Cancer and Blood Disorders, Milwaukee, Wisconsin
    Search for more papers by this author
  • Michael E. Kelly MD, PhD,

    1. Pediatric Hematology, Oncology, and Bone Marrow Transplant, Medical College of Wisconsin, Milwaukee, Wisconsin
    2. Midwest Center for Cancer and Blood Disorders, Milwaukee, Wisconsin
    Search for more papers by this author
  • Matthew J. Ehrhardt MD

    Corresponding author
    1. Pediatric Hematology, Oncology, and Bone Marrow Transplant, Medical College of Wisconsin, Milwaukee, Wisconsin
    2. Midwest Center for Cancer and Blood Disorders, Milwaukee, Wisconsin
    • Correspondence to: Matthew J. Ehrhardt, 8701 Watertown Plank Rd, MFRC3018, Milwaukee, WI 53226.

      E-mail: mehrhardt@mcw.edu

    Search for more papers by this author

  • Conflict of Interest: Nothing to report.

Abstract

Survival following childhood neuroblastoma is improving with low rates of secondary myeloid neoplasms. We describe a 13-month-old male with intermediate risk neuroblastoma who developed an isolated scalp therapy-related myeloid sarcoma (t-MS). Developmental delays and two distinct malignancies prompted constitutional evaluation. Chromosomal microarray identified a 7.3 Mb deletion of 9q22.32 to 9q31.1. He remains in remission 11 months following hematopoietic cell transplant. Unusual presentations of rare diseases necessitate a multidisciplinary approach and adaptation of standardized protocols to accommodate increased risks imposed by genetic variants. Pediatr Blood Cancer 2014;61:1701–1703. © 2014 Wiley Periodicals, Inc.

Ancillary